-
Aranda AM, Epstein AL, 2015: Herpes simplex virus type 1 latency and reactivation: an update[J]. Med Sci (Paris), 31, 506-514. doi: 10.1051/medsci/20153105012
-
Augustinova H, Hoeller D, Yao F, 2004: The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice[J]. J Virol, 78, 5756-5765. doi: 10.1128/JVI.78.11.5756-5765.2004
-
Awasthi S, Lubinski JM, Eisenberg RJ, Cohen GH, Friedman HM, 2008: An HSV-1 gD mutant virus as an entry-impaired live virus vaccine[J]. Vaccine, 26, 1195-1203. doi: 10.1016/j.vaccine.2007.12.032
-
BenMohamed L, Osorio N, Srivastava R, Khan AA, Simpson JL, Wechsler SL, 2015: Decreased reactivation of a herpes simplex virus type 1 (HSV-1) latency-associated transcript (LAT) mutant using the in vivo mouse UV-B model of induced reactivation[J]. J Neurovirol, 21, 508-517. doi: 10.1007/s13365-015-0348-9
-
Brehm M, Samaniego LA, Bonneau RH, DeLuca NA, Tevethia SS, 1999: Immunogenicity of herpes simplex virus type 1 mutants containing deletions in one or more alpha-genes: ICP4, ICP27, ICP22, and ICP0[J]. Virology, 256, 258-269. doi: 10.1006/viro.1999.9653
-
Cotter CR, Nguyen ML, Yount JS, López CB, Blaho JA, Moran TM, 2010: The virion host shut-off (vhs) protein blocks a TLR-independent pathway of herpes simplex virus type 1 recognition in human and mouse dendritic cells[J]. PLoS One, 5, e8684-. doi: 10.1371/journal.pone.0008684
-
David AT, Saied A, Charles A, Subramanian R, Chouljenko VN, Kousoulas KG, 2012: A herpes simplex virus 1 (McKrae) mutant lacking the glycoprotein K gene is unable to infect via neuronal axons and egress from neuronal cell bodies[J]. MBio, 3, e00144-00112.
-
Dumitrascu OM, Mott KR, Ghiasi H, 2014: A comparative study of experimental mouse models of central nervous system demyelination[J]. Gene Ther, 21, 599-608. doi: 10.1038/gt.2014.33
-
Farrell MJ, Dobson AT, Feldman LT, 1991: Herpes simplex virus latency-associated transcript is a stable intron[J]. Proc Natl Acad Sci USA, 88, 790-794. doi: 10.1073/pnas.88.3.790
-
Fatahzadeh M, Schwartz RA, 2007: Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management[J]. J Am Acad Dermatol, 57, 737-63; quiz 764. doi: 10.1016/j.jaad.2007.06.027
-
Garland SM, Steben M, 2014: Genital herpes[J]. Best Pract Res Clin Obstet Gynaecol, 28, 1098-1110. doi: 10.1016/j.bpobgyn.2014.07.015
-
Herrera FJ, Triezenberg SJ, 2004: VP16-dependent association of chromatin-modifying coactivators and underrepresentation of histones at immediate-early gene promoters during herpes simplex virus infection[J]. J Virol, 78, 9689-9696. doi: 10.1128/JVI.78.18.9689-9696.2004
-
Johnston C, Gottlieb SL, Wald A, 2016: Status of vaccine research and development of vaccines for herpes simplex virus[J]. Vaccine, 34, 2948-2952. doi: 10.1016/j.vaccine.2015.12.076
-
Kelly BJ, Fraefel C, Cunningham AL, Diefenbach RJ, 2009: Functional roles of the tegument proteins of herpes simplex virus type 1[J]. Virus Res, 145, 173-186. doi: 10.1016/j.virusres.2009.07.007
-
Koelle DM, Corey L, 2003: Recent progress in herpes simplex virus immunobiology and vaccine research[J]. Clin Microbiol Rev, 16, 96-113. doi: 10.1128/CMR.16.1.96-113.2003
-
Kukhanova MK, Korovina AN, Kochetkov SN, 2014: Human herpes simplex virus: life cycle and development of inhibitors[J]. Biochemistry (Mosc), 79, 1635-1652. doi: 10.1134/S0006297914130124
-
Lee K, Kolb AW, Larsen I, Craven M, Brandt CR, 2016: Mapping murine corneal neovascularization and weight loss virulence determinants in the herpes simplex virus 1 genome and the detection of an epistatic interaction between the UL and IRS/US regions[J]. J Virol, 90, 8115-8131. doi: 10.1128/JVI.00821-16
-
Leib DA, Bogard CL, Kosz-Vnenchak M, Hicks KA, Coen DM, Knipe DM, Schaffer PA, 1989: A deletion mutant of the latency-associated transcript of herpes simplex virus type 1 reactivates from thelatent state with reduced frequency[J]. J Virol, 63, 2893-2900.
-
Looker KJ, Magaret AS, May MT, Turner KM, Vickerman P, Gottlieb SL, Newman LM, 2015: Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012[J]. PLoS One, 10, e0140765-. doi: 10.1371/journal.pone.0140765
-
Loret S, Lippé R, 2012: Biochemical analysis of infected cell polypeptide (ICP)0, ICP4, UL7 and UL23 incorporated into extracellular herpes simplex virus type 1 virions[J]. J Gen Virol, 93, 624-634. doi: 10.1099/vir.0.039776-0
-
Maggioncalda J, Mehta A, Fraser NW, Block TM, 1994: Analysis of a herpes simplex virus type 1 LAT mutant with a deletion between the putative promoter and the 5' end of the 2[J]. 0-kilobase TranScript. J Virol, 68, 7816-7824.
-
Morrison LA, Knipe DM, 1997: Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1[J]. Virology, 239, 315-326. doi: 10.1006/viro.1997.8884
-
Paludan SR, Bowie AG, Horan KA, Fitzgerald KA, 2011: Recognition of herpesviruses by the innate immune system[J]. Nat Rev Immunol, 11, 143-154. doi: 10.1038/nri2937
-
Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F, 2013: Genome engineering using the CRISPR-Cas9 system[J]. Nat Protoc, 8, 2281-2308. doi: 10.1038/nprot.2013.143
-
Read GS, Karr BM, Knight K, 1993: Isolation of a herpes simplex virus type 1 mutant with a deletion in the virion host shutoff gene and identification of multiple forms of the vhs (UL41) polypeptide[J]. J Virol, 67, 7149-7160.
-
Saffran HA, Read GS, Smiley JR, 2010: Evidence for translational regulation by the herpes simplex virus virion host shutoff protein[J]. J Virol, 84, 6041-6049. doi: 10.1128/JVI.01819-09
-
Samady L, Costigliola E, MacCormac L, McGrath Y, Cleverley S, Lilley CE, Smith J, Latchman DS, Chain B, Coffin RS, 2003: Deletion of the virion host shutoff protein (vhs) from herpes simplex virus (HSV) relieves the viral block to dendritic cell activation: potential of vhs- HSV vectors for dendritic cell-mediated immunotherapy[J]. J Virol, 77, 3768-3776. doi: 10.1128/JVI.77.6.3768-3776.2003
-
Samoto K, Perng GC, Ehtesham M, Liu Y, Wechsler SL, Nesburn AB, Black KL, Yu JS, 2001: A herpes simplex virus type 1 mutant deleted for gamma34[J]. 5 and LAT kills glioma cells in vitro and is inhibited for in vivo reactivation. Cancer Gene Ther, 8, 269-277.
-
Sawtell NM, Triezenberg SJ, Thompson RL, 2011: VP16 serine 375 is a critical determinant of herpes simplex virus exit from latency in vivo[J]. J Neurovirol, 17, 546-551. doi: 10.1007/s13365-011-0065-y
-
Stanfield B, Kousoulas KG, 2015: Herpes Simplex Vaccines: Prospects of Live-attenuated HSV Vaccines to Combat Genital and Ocular infections[J]. Curr Clin Microbiol Rep, 2, 125-136. doi: 10.1007/s40588-015-0020-4
-
Strain AK, Rice SA, 2011: Phenotypic suppression of a herpes simplex virus 1 ICP27 mutation by enhanced transcription of the mutant gene[J]. J Virol, 85, 5685-5690. doi: 10.1128/JVI.00315-11
-
Tanaka M, Sata T, Kawaguchi Y, 2008: The product of the herpes simplex virus 1 UL7 gene interacts with a mitochondrial protein, adenine nucleotide translocator 2[J]. Virol J, 5, 125-. doi: 10.1186/1743-422X-5-125
-
Thompson RL, Sawtell NM, 1997: The herpes simplex virus type 1 latency-associated transcript gene regulates the establishment of latency[J]. J Virol, 71, 5432-5440.
-
Wagner EK, Flanagan WM, Devi-Rao G, Zhang YF, Hill JM, Anderson KP, Stevens JG, 1988: The herpes simplex virus latency-associated transcript is spliced during the latent phase of infection[J]. J Virol, 62, 4577-4585.
-
Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, Berman SM, Markowitz LE, 2006: Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States[J]. JAMA, 296, 964-973. doi: 10.1001/jama.296.8.964
-
Xu X, Che Y, Li Q, 2016a: HSV-1 tegument protein and the development of its genome editing technology[J]. Virol J, 13, 108-. doi: 10.1186/s12985-016-0563-x
-
Xu X, Fan S, Zhou J, Zhang Y, Che Y, Cai H, Wang L, Guo L, Liu L, Li Q, 2016b: The mutated tegument protein UL7 attenuates the virulence of herpes simplex virus 1 by reducing the modulation of alpha-4 gene transcription[J]. Virol J, 13, 152-. doi: 10.1186/s12985-016-0600-9
-
Yu X, Liu L, Wu L, Wang L, Dong C, Li W, Li Q, 2010: Herpes simplex virus type 1 tegument protein VP22 is capable of modulating the transcription of viral TK and gC genes via interaction with viral ICP0[J]. Biochimie, 92, 1024-1030. doi: 10.1016/j.biochi.2010.04.025